Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last hours
Enjoy this offer
* See conditions on site

Valuation: VYNE Therapeutics Inc.

Capitalization 17.33M 15.29M 14.25M 12.84M 23.85M 1.48B 26.77M 165M 65.07M 676M 65.01M 63.66M 2.47B P/E ratio 2025 *
-1.35x
P/E ratio 2026 * -1.41x
Enterprise value 17.33M 15.29M 14.25M 12.84M 23.85M 1.48B 26.77M 165M 65.07M 676M 65.01M 63.66M 2.47B EV / Sales 2025 *
24.8x
EV / Sales 2026 * 38.5x
Free-Float
91.6%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+4.00%
1 week-14.75%
Current month-21.80%
1 month-44.68%
3 months-62.86%
6 months-65.68%
Current year-68.96%
More quotes
1 week 0.96
Extreme 0.9606
1.26
1 month 0.96
Extreme 0.9606
1.54
Current year 0.96
Extreme 0.9606
4.3
1 year 0.96
Extreme 0.9606
4.3
3 years 0.96
Extreme 0.9606
9.9
5 years 0.96
Extreme 0.9606
237.6
10 years 0.96
Extreme 0.9606
291.6
More quotes
Manager TitleAgeSince
Chief Executive Officer 59 2020-02-29
Director of Finance/CFO 39 -
Chief Tech/Sci/R&D Officer 52 2020-02-29
Director TitleAgeSince
Director/Board Member 59 2020-02-29
Director/Board Member 71 2020-02-29
Director/Board Member 60 2014-12-31
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+4.00%-14.75%-59.69%-84.80% 17.33M
-0.35%+2.02%+53.38%+70.23% 35.61B
+1.12%+5.71%+58.10%+96.30% 28.58B
-1.18%+1.12%+45.15%-32.74% 24.74B
-0.39%+6.37%+1.78%-36.13% 23.72B
+0.31%+8.29%+664.79%+2,564.67% 19.2B
-2.68%+2.95%-32.84%-36.92% 12.75B
-0.83%+1.27%+85.17%-57.60% 12.38B
+2.07%-0.87%+206.95%+252.09% 12.3B
-1.10%-6.63%+106.08%+139.49% 11.56B
Average +0.10%+0.60%+112.89%+287.46% 18.09B
Weighted average by Cap. -0.25%+3.05%+121.03%+311.57%
See all sector performances

Financials

2025 *2026 *
Net sales 700K 618K 576K 519K 963K 59.63M 1.08M 6.68M 2.63M 27.32M 2.63M 2.57M 99.94M 450K 397K 370K 333K 619K 38.33M 695K 4.29M 1.69M 17.56M 1.69M 1.65M 64.24M
Net income -39.36M -34.73M -32.37M -29.17M -54.17M -3.35B -60.8M -376M -148M -1.54B -148M -145M -5.62B -44.58M -39.33M -36.66M -33.03M -61.35M -3.8B -68.85M -425M -167M -1.74B -167M -164M -6.36B
Net Debt - -
More financial data * Estimated data
Logo VYNE Therapeutics Inc.
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Employees
13
More about the company
Date Price Change Volume
25-05-23 1.040 $ +4.00% 1,329,550
25-05-22 1.000 $ 0.00% 282,526
25-05-21 1.000 $ -13.04% 754,014
25-05-20 1.150 $ -5.74% 250,853
25-05-19 1.220 $ 0.00% 261,821

Delayed Quote Nasdaq, May 23, 2025 at 04:00 pm EDT

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.040USD
Average target price
6.375USD
Spread / Average Target
+512.98%
Consensus

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
BENEFIT NOW